Identification of predictive biomarkers for cancer immunotherapy
Despite recent impressive advances in cancer immunotherapy, the majority of cancer patients do not respond to any of the available immunotherapeutics. Therefore, there is an urgent need for reliable biomarkers able to identify patients that would benefit from this treatment option. The EU-funded GlyCANswer project aims to elucidate how the cancer glycoproteome dictates the immune response to facilitate the development of new strategies for immunotherapy and to identify predictive biomarkers for treatment response. The project's objective is to uncover the interplay between the cancer cell glycoproteome and immune recognition in lung and breast cancer, using a combination of glycoproteomics, glycomics and immune profiling approaches in mouse models and cell culture systems.